This story was originally published July 22.
Cancer Research UK has selected Illumina as a preferred service provider for whole-genome sequencing of cancer genomes as part of its contribution to the International Cancer Genome Consortium.
Illumina's sequencing services will first be applied toward prostate and esophageal cancers and will include whole-genome sequencing on the HiSeq 2000 of up to 1,500 samples over the next three years on both tumor and normal genomes.
In addition, Illumina will also provide expression and epigenetic services to characterize transcriptomic and epigenomic changes in the tumors.
Due to advances in sequencing technology, "we're now entering a 'golden era' for cancer research," Fiona Hemsley, head of strategic projects at Cancer Research UK, said in a statement.
Financial details of the agreement were not disclosed.